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Abstract
Two to three percent of the world’s population is chronically infected with hepatitis C virus (HCV) and thus at risk of
developing liver cancer. Although precise mechanisms regulating HCV entry into hepatic cells are still unknown, several cell
surface proteins have been identified as entry factors for this virus. Among these molecules, the tetraspanin CD81 is
essential for HCV entry. Here, we have identified a partner of CD81, EWI-2wint, which is expressed in several cell lines but
not in hepatocytes. Ectopic expression of EWI-2wint in a hepatoma cell line susceptible to HCV infection blocked viral entry
by inhibiting the interaction between the HCV envelope glycoproteins and CD81. This finding suggests that, in addition to
the presence of specific entry factors in the hepatocytes, the lack of a specific inhibitor can contribute to the hepatotropism
of HCV. This is the first example of a pathogen gaining entry into host cells that lack a specific inhibitory factor.
Citation: Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, et al. (2008) The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry. PLoS
ONE 3(4): e1866. doi:10.1371/journal.pone.0001866
Editor: Nina Papavasiliou, The Rockefeller University, United States of America
Received August 9, 2007; Accepted February 18, 2008; Published April 2, 2008
Copyright:  2008 Rocha-Perugini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the ‘‘Institut Fe ´de ´ratif de Recherche-142’’ (IFR142) and by grants from the CNRS and the « Agence Nationale de Recherches
sur le Sida et les he ´patites virales » ANRS. V R-P was supported by a fellowship from the « Institut Pasteur de Lille/Re ´gion Nord Pas-de-Calais ». DD was supported
by a fellowship from the ANRS. FH was supported by a fellowship from the French Ministry of Research. JD is an international scholar of the Howard Hughes
Medical Institute.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jean.dubuisson@ibl.fr (JD); laurence.cocquerel@ibl.fr (LC)
. These authors contributed equally to this work.
Introduction
Hepatitis C virus (HCV) infection is a global public health
problem affecting over 130 million individuals worldwide; its
symptoms including chronic hepatitis, liver cirrhosis, and hepato-
cellular carcinoma [1]. Unfortunately, no vaccine is currently
available to prevent new infections and the current treatments are
not fully efficient [2]. Clearly, new therapeutic strategies are
urgently required.
Over the past decade, due to the lack of a cell culture system
supporting production of infectious virus particles, several
surrogate models have been developed to facilitate analysis of
the HCV life cycle. Among these models, pseudoparticles
(HCVpp), consisting of native HCV envelope glycoproteins
assembled onto retroviral core particles [3,4] have been useful in
investigating the HCV entry process. More recently, however,
production of infectious HCV particles in cell culture (HCVcc) has
finally become possible [5,6,7]. This powerful system is based on
the transfection of the human hepatoma cell line Huh-7 with the
cloned JFH1 genome that replicates and produces infectious
particles.
HCV encodes two envelope glycoproteins, E1 and E2, that
interact to form a noncovalent E1E2 heterodimer [8] which is
present at the surface of HCV particles [6], and is therefore the
obvious candidate ligand for cellular receptor(s). Although the
early steps of viral entry have yet to be elucidated, several cell-
surface expressed molecules have been proposed as entry factors
for HCV (reviewed in [9]). Among these molecules, the
tetraspanin CD81 and the scavenger receptor class B type I (SR-
BI) have been shown to play major roles in HCV entry. However,
co-expression of these two molecules in non-hepatic cell lines does
not lead to HCV entry [10], suggesting that additional molecule(s)
are involved in control of HCV entry. Recently, the tight-junction
components Claudins (CLDN-1, CLDN-6, CLDN-9) have been
identified as additional key factors for HCV infection [11,12].
Interestingly, CLDN-1 is the first entry factor shown to confer
susceptibility to HCV when ectopically expressed in non-hepatic
cells. Nevertheless, although CLDN-1 subcellular distribution
seems to modulate HCV permissivity [13], some human cell lines
expressing CD81, SR-BI and CLDN-1 remain resistant to HCV
entry suggesting that one or more human-specific HCV entry
factor(s) remain to be discovered [11].
CD81 belongs to the tetraspanin family. Members of this family
organize and regroup their associated transmembrane proteins
and are involved in various functions such as cell morphology,
motility, fusion and signalling [14,15]. A major characteristic of
tetraspanins is their ability to interact with each other and with
other transmembrane proteins, thus building membrane multi-
molecular complexes, collectively referred to as the tetraspanin
web [16,17]. Within this network of interactions, tetraspanins form
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tetraspanin partners. These primary interactions are direct, highly
specific and occur at high stoichiometry. Two major partners have
been identified for CD81, EWI-F (also called CD9P-1, FPRP or
CD315) and EWI-2 (also called PGRL, IgSF8 or CD316)
[18,19,20,21,22], which may provide a link between the
tetraspanin web and the actin cytoskeleton by interacting with
Ezrin, an Ezrin-Radixin-Moesin (ERM) protein [23]. Although its
function is still unclear, EWI-2 seems to participate in the
regulation of cellular functions such as aggregation, spreading,
motility and migration [24,25,26].
In this work, we identified a cleavage product of EWI-2, which
associates with CD81 and inhibits its interaction with the HCV
envelope glycoproteins. Most importantly, this molecule, that we
called EWI-2wint (EWI-2 without its N-terminus), has an
inhibitory effect on HCV entry, highlighting a potential new
mechanism for the regulation of cellular invasion by this pathogen.
Results
A CD81 partner blocks the interaction between CD81
and HCV envelope glycoproteins
Tetraspanin microdomains are typically disrupted by Triton X-
100 (TX), but are retained in less hydrophobic detergents such as
Brij97 (Bj). In addition, the replacement of divalent cations
(CaMg) by EDTA in the Brij97 lysis buffer causes a disruption of
tetraspanin/tetraspanin interactions but conserves the tetraspa-
nin/partner interactions [18] (Figure 1A). These biochemical
properties allowed us to investigate whether the interaction
between CD81 and E1E2 heterodimers is similar when CD81 is
embedded or not in a tetraspanin web or in a primary complex.
For this purpose, we analysed the interaction between E1E2
heterodimers and CD81 in several cell lines lysed in different
detergent conditions (Figure 1A and Table 1). The E1E2
complexes were immobilized on agarose beads bound to a
conformation-sensitive monoclonal antibody (mAb H53). Analysis
of these agarose-bound complexes under non-reducing conditions
[27] showed proper folding of the heterodimers in the different
detergent conditions (data not shown). As positive and negative
controls, we used anti-CD81 and irrelevant mouse (Cont) mAbs,
respectively. A recombinant soluble form of the CD81 large
extracellular loop (CD81-LEL) [28] was also used as a control.
CD81 from Molt-4 and 293T cells interacted with E1E2
heterodimers under all detergent conditions, as did the CD81-
LEL (Figure 1A). In contrast, CD81 from Daudi and Ramos cells
did not interact with E1E2 heterodimers when tetraspanin webs or
primary complexes were conserved (Figure 1A, Bj/CaMg and Bj/
EDTA, respectively). Daudi cells also did not react with E1E2
glycoproteins derived from HCVpp (data not shown). Together,
our results suggest that a CD81 partner, present on Daudi and
Ramos cells, blocks the interaction between CD81 and HCV
glycoproteins. Testing of other cell lines indicated that such a
CD81 partner is probably also present in other cell lines such as
A431, a squamous carcinoma cell line (Table 1).
To identify the CD81 partner blocking the interaction between
CD81 and E1E2, we performed co-immunoprecipitation exper-
iments using Bj/EDTA lysates from surface biotinylated cells.
Under these conditions, only partners directly associated in
primary complexes co-precipitate with CD81. In all cell lines, a
70-kDa surface protein, corresponding to EWI-2 [18,21] was co-
precipitated with CD81 (Figure 1B). EWI-F, the second major
CD81/CD9 partner [19,22] was also co-precipitated with CD81
and CD9 in 293T cells. To confirm the specificity of EWI-2 and
EWI-F, these proteins were immunoprecipitated with specific
mAbs 8A12 and 1F11, respectively (data not shown). Additional
bands were also observed in these cells, but the identity of the
corresponding proteins is unknown. Interestingly, an additional
,55 kDa surface protein co-precipitated with CD81 in Daudi and
Ramos cells but not in Molt-4 and 293T cells. This protein, which
we have named EWI-2wint, has been previously proposed as a
cleavage product of EWI-2 that remains associated with CD81
and CD9 [18,21]. Furthermore, transfection of EWI-2 siRNA into
Daudi cells reduced both the expression of EWI-2 and of EWI-
Figure 1. The interaction between HCV glycoproteins and
CD81 is blocked when CD81 interacts with partner protein(s).
A, HCV E1E2 heterodimers immobilized onto anti-E2 coated beads
interacted with CD81 in all cells lysed in Triton X-100 (TX). However, the
interaction of HCV-E1E2 with CD81 was blocked in Daudi and Ramos
cells lysed in Brij (Bj). Maintenance of CD81 with other tetraspanins (T)
and partners (P) is disrupted by the indicated lysis conditions, as
diagrammed. Anti-CD81 and irrelevant (Cont) mAbs were used in
immunoprecipitations as controls. Precipitation of CD81 was revealed
by western blotting with the anti-CD81 5A6 mAb. CD81-LEL corre-
sponds to the large extracellular loop of CD81 fused to the glutathione-
S transferase. B, After cell surface biotinylation, the indicated cell lines
were lysed with Bj/EDTA, immunoprecipitated with 5A6 mAb and the
proteins revealed by Western blotting with HRP-conjugated streptavi-
din. The values on the right are molecular sizes in kilodaltons. C, EWI-
2wint production is directly connected to EWI-2 expression. Daudi cells
interfered with negative siRNA or EWI-2 siRNA were biotinylated, lysed
in Bj/EDTA, immunoprecipitated with the anti-CD81 5A6 mAb or an
anti-EWI-2 mAb (8A12) and blotted sequentially with HRP-conjugated
streptavidin and 5A6 mAb.
doi:10.1371/journal.pone.0001866.g001
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directly connected to EWI-2 expression. We performed additional
co-immunoprecipitation experiments using different surface bio-
tinylated cell lysates (Table 1). Co-immunoprecipitation of EWI-
2wint with CD81 correlated with the inhibition of CD81-E1E2
interaction in mild detergents. Conversely, cells for which CD81
bound to E1E2 did not express this protein. It is worth noting that
primary hepatocytes and hepatoma cells do not have detectable
levels of EWI-2wint. We also analysed SR-BI and CLDN-1
expression in the same cell lines, and the lack of interaction
between CD81 and E1E2 glycoproteins cannot be correlated with
the absence of these molecules (Table 1, see squamous carcinoma,
A431). Altogether, our results suggest that EWI-2wint probably
corresponds to the CD81 partner blocking the interaction between
CD81 and HCV glycoproteins.
EWI-2wint corresponds to EWI-2 with its amino-terminus
deleted
To confirm that EWI-2wint is a cleavage product of EWI-2, we
constructed an EWI-2 cDNA with a C-terminal FLAG epitope tag
(EWI-2FLAG), as described previously [21]. CHO cells stably co-
expressing human CD81 and EWI-2FLAG (CHO/CD81+EWI-
2FLAG) were surface biotinylated, lysed in Bj/EDTA (Figure 2A)
or TX/EDTA (Figure 2D) and analysed in immunoprecipitation
experiments. Upon EWI-2FLAG coexpression with CD81,
EWI-2wint was detected following anti-FLAG immunoprecipita-
tion or co-immunoprecipitation with CD81 (wint-FLAG ;
Figure 2A). These results and Western blotting analyses (data
not shown) showed that EWI-2wint still contains the C-terminal
FLAG epitope, making EWI-2wint an authentic cleavage product
of EWI-2. It is interesting to note that EWI-2wint was not
recognized by our anti-EWI-2 mAb and that only a small fraction
of CD81 co-immunoprecipitated with EWI-2 products, as
previously observed [18]. Two smaller proteins of ,50, and
45 kDa, which remained associated with CD81 and probably
correspond to additional cleavage products of EWI-2 were also
detected (asterisks in Figure 2).
EWI-2 belongs to a novel family of immunoglobulin (Ig)
proteins, which also includes EWI-F/CD9P-1/PGRL, EWI-101/
CD101/V7 and EWI-3/IgSF3 [21]. The members of this family
share a conserved EWI motif and contain an ectodomain
composed of V-type Ig domains, a transmembrane domain and
a short highly charged cytoplasmic tail [21]. EWI-2 contains 4 Ig
domains (Figure 3).
To identify the sequence of EWI-2wint, EWI-2FLAG and wint-
FLAG proteins were purified by immunoaffinity from a Triton X-
100 lysate of CHO/CD81+EWI-2FLAG and fractionated by
SDS-PAGE. The bands corresponding to EWI-2FLAG and wint-
FLAG were excised after colloidal blue staining and digested with
trypsin or V8 endoproteinase Glu C and the resulting peptides
analysed by mass spectrometry (Table 2). Interestingly, only
Table 1. In vitro interaction of HCV E1E2 heterodimers with CD81 and expression of cell markers.
Cell lines E1E2/CD81 interaction
1 SR-BI
2 Claudin-1
2 CD81
3 EWI-2
3 EWI-2wint
4
Hematopoietic cell lines
B cells
Daudi - ++ - ++ +
Ramos - ++ - ++ +
OCI-LY8 +/2 ++ - ++ + /2
T cells
Jurkat +/2 +/2 - ++ + /2
Molt-4 ++ /2 - ++ -
Myeloid cells -
U937 - +/2 -- --
U937-CD81 ++ /2 - + --
PBMC +/2 ND ND ++ + /2
Non Hematopoietic cell lines
Fetal kidney, 293T ++ - ++ -
Squamous carcinoma, A431 - +++ ++
Hepatocyte carcinoma
Huh-7 ++ + + + + -
HepG2-CD81 ND ND ND ++ -
PLC/PRF-5 ND ND ND ++ -
Primary hepatocytes ++ + + + -
1The ratio [CD81 band intensity in E1E2 IP in Bj/EDTA buffer]/[CD81 band intensity in E1E2 IP in TX/EDTA buffer] was used to evaluate the E1E2/CD81 interaction: -, #0.1;
+/2, .0.1–0.7,; +,$0.7
2Expression of SR-BI and Claudin-1 detected by WB with Cla-1 mAb and JAY.8 polyclonal Ab, respectively. Amount of each protein was compared to Huh-7 cells. The
ratio [protein band intensity of the cell line]/[protein band intensity of Huh-7 cell line] was used: -, ,0.1; +/2, $0.1–0.4,; +, $0.4–1,; ++, $1. Actin proteins were used
for normalization.
3Cell surface expression of CD81 and EWI-2 proteins detected by flow cytometry with 5A6 and 8A12 mAbs, respectively. Analyses gave mean fluorescence intensities
(MFI) in the range of 3–6 for negative controls and intensities over 10 for specific stainings.
4Expression detected by co-immunoprecipitation with CD81 as described in Figure 1B. The ratio [EWI-2wint band intensity]/[CD81 band intensity] was used to evaluate
the expression of EWI-2wint: -, #0.01; +/2, .0.01–0.1#; +, .0.1
doi:10.1371/journal.pone.0001866.t001
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domain (Ig 1 domain) of EWI-2 were not present in the wint-
FLAG band, suggesting that this domain may be absent in the
EWI-2wint protein. Indeed, sequencing of purified proteins by
Edman degradation revealed that the N-terminal sequence of
EWI-2wint corresponds to the QAPTS amino acids (Table 2)
residues 166 to 170, which are located within the spacer separating
the Ig1 and Ig2 domains of EWI-2 (Figure 3). Altogether, these
results indicate that EWI-2wint corresponds to EWI-2 without its
Ig 1 domain. Following these results, we chose to name this protein
EWI-2wint for EWI-2 without its N-terminus.
Expression of EWI-2wint in HCV target cells
To characterize EWI-2wint, we cloned it as a FLAG-tagged
protein in an expression vector (pcDNA3.1/wint-FLAG). CHO
cells transfected with pcDNA3.1/wint-FLAG produced EWI-
2wint and the two additional cleavage products (asterisks), as
shown in Figure 2B and 2E. To further test the role of EWI-2wint
in HCV infection, we tried to obtain hepatoma cells (Huh-7) stably
expressing EWI-2wint. However, despite several attempts, EWI-
2wint expression in cellular clones could not be detected by cell
surface biotinylation and immunoprecipitation or by western
blotting experiments (data not shown), suggesting that this protein
was poorly expressed in these cells. To circumvent this problem,
we added a single Arg residue into the EWI-2FLAG sequence
directly upstream to Q
166 amino acid (asterisk, Figure 3), making
an EWI-2FLAG protein with a RGRR cleavage motif for furin
(pcDNA3.1/EWI-2FLAG
fur), a trans-Golgi network associated
endopeptidase. This strategy, when tested in CHO cells transfect-
ed with pcDNA3.1/EWI-2FLAG
fur, yielded a high amount of the
EWI-2wint protein, as shown in Figure 2C and 2F. Furthermore,
EWI-2wint could be detected by direct immunoprecipitation or by
co-immunoprecipitation with CD81 in Huh-7 cells stably expressing
EWI-2FLAG
fur (wint-FLAG, Figure 4D). Almost no whole EWI-
2FLAG protein reached the surface of Huh-7/EWI-2FLAG
fur cells,
indicating that the cleavage of EWI-2FLAG
fur by furin was highly
efficient in these cells. It should be noted that at least one additional
cleavage product of EWI-2FLAG (asterisk, Figure 4D) was detected
as in CHO cells. The association of one or two additional cleavage
products with the production of EWI-2wint suggests that the first
cleavage of EWI-2 allows the unmasking of one or two additional
sites that are not accessible in the whole protein. In contrast, Huh-7
cells (Figure 4A), Huh-7 stably transfected with the empty vector
(pcDNA3.1, Figure 4B) or with EWI-2FLAG, expressing a N-
terminal HA epitope (HAEWI-2FLAG, Figure 4C) were devoid of
EWI-2wint. In Huh-7 cells stably transfected with HAEWI-2FLAG,
the tagged molecule was detected following co-immunoprecipitation
with CD81 or by direct immunoprecipitation with anti-FLAG or
anti-HA mAbs, as compared to control cells (Figure 4). The anti-
CD81 and anti-FLAG antibodies precipitated different amounts of
wint-FLAG in Huh-7/EWI-2FLAG
fur cells (Figure 4D). This might
be due to differences in the affinity of the antibodies, as has been
previously observed when EWI-2 and CD81 were coprecipitated
[18]. Alternative possibilities are that i) homodimerization and
heterodimerization of EWI-2 and CD81 modulate recognition by
antibodies,asdescribed[29,30],ii)bindingoftheanti-FLAGmAbat
the C-terminus of EWI-2wint induces a dissociation of the CD81/
EWI-2wint complexes.
EWI-2wint inhibits HCV infection
We then sought to determine whether EWI-2wint is able to
modulate HCV infection of Huh-7 target cells. Originally we used
Figure 2. EWI-2wint is a cleavage product of EWI-2. CHO cells were (co)-transfected with pcDNA3.1/CD81 and pcDNA3.1/EWI-2FLAG (A and D),
with pcDNA3.1/wint-FLAG (B and E), or with pcDNA3.1/CD81 and pcDNA3.1/EWI-2FLAG
fur (C and F). EWI-2FLAG
fur corresponds to EWI-2FLAG in
which a furin cleavage site has been engineered. After cell surface biotinylation, cells were lysed with Bj/EDTA (A–C) or TX/EDTA (D–F) and proteins
were immunoprecipitated with the indicated mAbs. Proteins were revealed by Western blotting with HRP-conjugated streptavidin. Asterisks indicate
additional cleavage products of EWI-2.
doi:10.1371/journal.pone.0001866.g002
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Huh-7 cells expressing EWI-2FLAG
fur, HAEWI-2FLAG,
pcDNA3.1 or naı ¨ve Huh-7 cells. In the absence of a reporter
gene in HCVcc, infection levels were evaluated by immunofluo-
rescence (Figure 5A) and western blotting (Figure 5B), 40 h post-
infection. Interestingly, we observed a reduction in HCVcc
infection level in cells expressing EWI-2FLAG
fur, whereas it
remained unmodified in control cells (Figure 5C). It is worth
noting that in HAEWI-2FLAG cells, the HCVcc infection level
was similar to that of pcDNA3.1 cells, indicating that ectopic
expression of HAEWI-2FLAG does not affect HCV infection. In
addition, flow cytometry analyses ruled out any potential bias due
to different levels of CD81 cell surface expression on clones
(Figure 5D). Altogether, these results indicate that EWI-2wint
produced in Huh-7/EWI-2FLAG
fur cells inhibits HCV infection.
EWI-2wint blocks HCV entry into target cells
The life cycle of HCV can be divided into three major steps :
entry of the virus into its target cells by receptor-mediated
endocytosis, cytoplasmic and membrane-associated replication of
the RNA genome, and assembly and release of the progeny
virions.
To analyze the effect of EWI-2wint expression on HCV genome
replication, we compared the efficiency of RNA replication and
virus production between transfected cell lines expressing or
lacking EWI-2wint. We transfected equal amounts of RNA
corresponding to the full-length JFH1 genome [6] into the
different cell lines (Figures 6A and 6B). Immunofluorescence
analyses of transfected cells showed similar positivity for HCV
anti-core antibody at 40 h post-transfection. Flow cytometry
analyses using an anti-NS3 mAb showed that, although slightly
stronger in Huh-7 cells, viral expression was similar in cellular
clones that lacked or expressed EWI-2wint (Figure 6B), indicating
that EWI-2wint does not affect HCV genome replication. Next, to
assess the effect of EWI-2wint on the assembly and/or egress of
particles, the culture medium of each transfected cell line was
harvested and used to infect naı ¨ve Huh-7 cells. Through core-
specific immunofluorescence staining, we found that Huh-7 cells
were similarly infected by virus produced from all transfected
cellular clones (data not shown), suggesting that EWI-2wint does
not affect HCV assembly and release.
Our observations indicate that EWI-2wint likely affects an early
step in the HCV life cycle. To test this hypothesis, we analyzed the
effect of EWI-2wint on the infectivity of retroviral particles
pseudotyped with HCV E1E2 proteins (Figure 6C). Use of
HCVpp enables the analysis of the HCV entry step. We generated
particles pseudotyped with HCV envelope glycoproteins from 1a
and 2a genotypes (HCVpp 1a and HCVpp 2a, respectively) and
control particles pseudotyped with the envelope glycoprotein G of
vesicular stomatitis virus (VSVpp). As shown in Figure 6C,
HCVpp infectivity was reduced in cells expressing EWI-2wint
whereas it remained unmodified in control cells. Expression of
EWI-2wint in target cells had no effect on VSVpp infectivity. It is
interesting to note that HAEWI-2FLAG expression slightly
Figure 3. Alignment of EWI-2 sequence and the deduced EWI-2wint sequence. Asterisk indicates the position at which an Arg (R) residue
was introduced to make a furin cleavage site. Underlined amino acids correspond to the signal peptide of EWI-2. The four Ig domains are colored.
Amino acid residues corresponding to the putative transmembrane domain are in italics and those corresponding to the cytoplasmic tail are bolded.
doi:10.1371/journal.pone.0001866.g003
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indicate that EWI-2wint inhibits the entry stage of HCV lifecycle,
likely by interacting with CD81.
To determine whether the lower level of HCV infection observed
in EWI-2wint producing cells resulted from a reduced interaction
between HCV glycoproteins and CD81, we compared the
interaction between E1E2 and CD81 in Huh-7/pcDNA3.1 and
Huh-7/EWI-2FLAG
fur cells, as detailed in Figure 1. Interestingly,
our results demonstrated reduced interaction between E1E2 and
CD81 in Huh-7/EWI-2FLAG
fur cells lysed in Bj/EDTA which
conserves tetraspanins/partners interactions, as compared to cells
lysed inTX/EDTA(Figure 6D). In contrast,the bindingof E1E2to
CD81 was similar in Huh-7/pcDNA3.1 cells in both detergent
conditions. These data indicatethat the inhibitionof HCVinfection
by EWI-2wint correlates with its capacity to inhibit the interaction
between E2 glycoprotein and CD81.
In order to carry out statistical analyses of EWI-2wint effect on
HCV infection, we next generated JFH1-based Renilla luciferase
(R-Luc) reporter HCVcc and infected Huh-7 cells that lacked or
expressed EWI-2wint (Figure 7A). Cellular populations
(pcDNA3.1, HAEWI-2FLAG and EWI-2FLAG
fur POP) and
individual cellular clones (EWI-2FLAG
fur A1, A6, B14, C1) have
been used in these experiments. In parallel, we infected these cells
with HCVpp 1a, HCVpp 2a or VSVpp (Figure 7B), as described
in Figure 6. Our results showed that EWI-2wint expression
inhibits HCVcc infectivity up to 80% (Figure 7A; EWI-2FLAG
fur
A6) confirming our previous findings (Figure 5). It is noteworthy
that EWI-2wint was less effective, reducing HCVpp infectivity
only by 40–50% (Figure 7B; EWI-2FLAG
fur A1), which might be
due to slight differences between HCVpp and HCVcc in the entry
stages, as recently reported by others [31]. Once again, this study
shows that EWI-2wint expression in Huh-7 cells leads to a
significant reduction of HCV infection.
Discussion
Here, we identified a novel CD81 associated protein, EWI-
2wint, which is able to inhibit HCV entry into target cells by
Table 2. Mass spectrometric analyses and N-terminal sequencing of EWI-2 and EWI-2wint proteins
SEQUENCE POSITION MASS ENZ EWI-2 EWI-2wint
EVLVPEGPLYR 29–39 1271 Tryp + -
DTQFSYAVFK 83–92 1205 Tryp + -
VVAGEVQVQR 95–104 1084 Tryp + -
LQAQDAGIYECHTPSTDTR 117–135 2163 Tryp + -
VLPDVLQVSAAPPGPR 148–163 1615 Tryp + -
MTVHEGQELALGCLAR 174–189 1784 Tryp ++
MTVHEGQELALGCLAR 174–189 1800 Tryp ++
HTHLAVSFGR 195–204 1124 Tryp ++
SVPEAPVGR 205–213 911 Tryp ++
STLQEVVGIR 214–223 1101 Tryp ++
SDLAVEAGAPYAER 224–237 1448 Tryp ++
LAAGELR 238–244 729 Tryp ++
MVVGGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEK 255–289 3690 Tryp ++
AVLAHVDVQTLSSQLAVTVGPGER 291–314 2447 Tryp ++
HAAYSVGWEMAPAGAPGPGR 338–357 1981 Tryp ++
HAAYSVGWEMAPAGAPGPGR 338–357 1997 Tryp ++
LVAQLDTEGVGSLGPGYEGR 358–377 2018 Tryp ++
LEAARPGDAGTYR 393–405 1376 Tryp ++
SRPLPVHVR 427–435 1060 Tryp ++
GGPPGLR 468–474 653 Tryp ++
LHSLGPEDEGVYHCAPSAWVQHADYSWYQAGSAR 531–564 3844 Tryp ++
AVVLKIARLQAQD 109–121 1424 Glu-C + -
CHTPSTDTRYLGSYSGKVE 127–145 2157 Glu-C + -
VVGIRSDLAVE 219–229 1157 Glu-C ++
GSWAQIAEKRAVLAHVD 281–297 1850 Glu-C ++
MAPAGAPGPGRLVAQLDTE 347–365 1866 Glu-C ++
AASARSRPLPVHVREE 422–437 1774 Glu-C ++
AVAWLAGGTVYRGE 443–456 1449 Glu-C ++
LGVRPGGGPVSVE 508–520 1223 Glu-C ++
LVGPRSHRLRLHSLGPEDE 521–539 2168 Glu-C ++
N-term REVLV QAPTS
Tryp: trypsine; Glu-C: V8 endoproteinase Glu C
doi:10.1371/journal.pone.0001866.t002
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PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e1866Figure 4. EWI-2wint expression in Huh-7 cells. After cell surface biotinylation, Huh-7 cells (A) stably expressing pcDNA3.1 (B), HAEWI-2FLAG (C)
or EWI-2FLAG
fur (D) were lysed with Bj/EDTA and analyzed by immunoprecipitation with indicated mAbs. Proteins were revealed by Western blotting
with HRP-conjugated streptavidin. The molecular weights of the prestained molecular ladder are indicated in KDa. The asterisk indicates an additional
cleavage product of EWI-2. The band indicated by a light arrow likely corresponds to a dimer of CD81, and the band indicated by a full arrow to an
unidentified EWI-2 associated protein.
doi:10.1371/journal.pone.0001866.g004
Figure 5. EWI-2wint inhibits HCVcc infection. Cell clones were infected with JFH1 HCVcc and infectivity was analyzed by indirect
immunofluorescence with an anti-C mAb (A) or Western blotting with an anti-E2 mAb (B). The fields displayed in (A) contained similar numbers of
cells. C, Infection levels were measured by quantification with NIH Image 1.62 of the intensities of HCV E2 bands. The results are presented as
percentages of HCVcc infection relative to the infection of Huh-7/pcDNA3.1 cells. Infection levels of three independent experiments are reported as
the mean with standard deviation bars. D, CD81 expression on the surfaces of cells expressing or not EWI-2wint. Cells were stained by using an anti-
CD81 mAb (5A6) and secondary antibody conjugated with PE. Cont corresponds to Huh-7 cells that were stained only with the secondary antibody.
doi:10.1371/journal.pone.0001866.g005
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This finding indicates that the early steps of HCV entry into its
target cells involve tight control of CD81 accessibility to the viral
particle.
EWI-2wint may inhibit HCV entry by reducing E1E2-CD81
interactions for a number of possible reasons. EWI-2wint may
reduce CD81 accessibility to envelope glycoproteins by steric
hindrance. Alternatively, the association of EWI-2wint with CD81
may induce conformational modifications in CD81, blocking the
binding of HCV heterodimers. Although the exact role of CD81 in
the course of virus infection is not well defined, it is a key molecule
required for productive infection by HCVpp and HCVcc of Huh-
7 cells [3,4,5,6,7,10,32]. Moreover, most recently CD81 was
shown to be required for the infection of primary hepatocytes by
serum-derived HCV [33]. Previous studies have suggested that
CD81 may not be required for the first attachment step, but rather
function as a post-attachment entry co-factor [34,35,36]. Very
recently, it has been shown that CLDN-1, 6 and 9 membrane
proteins localized at tight junctions, are additional entry factors for
HCV [11,12,37], indicating that HCV entry might involve a
complex multistep process. CD81 might potentially be required
for a post-binding step such as escorting the particle into the
endocytic pathway or priming it for the pH triggered fusion
mechanism. The association of EWI-2wint with CD81 could block
such entry stages. Since our preliminary results suggest that CD81
and EWI-2wint likely colocalize in an endosomal compartment
(unpublished data), EWI-2wint might exert its inhibitory effect on
CD81 functionality in the endosomes. In addition, EWI-2wint
may interfere with actin polymerization potentially required for
HCV entry. Indeed, HCV replication requires microtubule and
actin polymerization [38] and CD81 engagement leads to actin
rearrangement [39,40]. Furthermore, it has also recently been
shown that CD81 and EWI-2 interact with Ezrin, an actin-linking
ERM protein [23]. Lastly, we cannot exclude the possibility that
EWI-2wint blocks other signaling pathways necessary for viral
entry.
EWI-2wint is a cleavage product of the EWI-2 protein. The
proteolytic cleavage of EWI-2 Ig1 domain occurs downstream of
Figure 6. EWI-2wint inhibits the entry stage of HCV life cycle by reducing the interaction between E1E2 and CD81. A, EWI-2wint does
not interfere with HCV replication. The indicated Huh-7 cell lines were transfected with the full-length JFH1 genome, and expression of the core
antigen was evaluated at 40 h post-transfection. The displayed fields contained similar numbers of cells. B, NS3 expression in JFH-1 transfected cells.
Cells were stained by using an anti-NS3 mAb (486-D39) and secondary antibody conjugated with PE. Cont corresponds to untransfected Huh-7 cells.
C, Huh-7 cell lines were incubated for 3 h with virus pseudotyped with HCV envelope glycoprotein (HCVpp) or VSV G envelope protein (VSVpp).
HCVpp were generated with envelope proteins from 1a (HCVpp 1a) or 2a (HCVpp 2a) genotype. The inoculum was then removed and the cells were
further incubated. At 2 days post-inoculation, cells were lysed and processed to measure the luciferase activity. The luciferase activities were
normalized for protein concentration in each cell lysate. The results are presented as relative percentages to HCVpp infectivity on Huh-7 cells. Results
are reported as the mean6S.D. of three independent experiments. Pseudotyped particles produced in the absence of envelope proteins were used as
controls. The mean fluorescence activity of such particles represented less than 2% of the activity measured for HCVpp. D, In vitro interaction of E1E2
heterodimers with CD81 from Huh-7/EWI-2FLAG
fur and Huh-7/pcDNA3.1. This assay was performed as described in Figure 1. The ratio [CD81 band
intensity in E1E2 IP in Bj/EDTA buffer]/[CD81 band intensity in E1E2 IP in TX/EDTA buffer] was 0,27 and 0,84 in Huh-7/EWI-2FLAG
fur and Huh-7/
pcDNA3.1, respectively.
doi:10.1371/journal.pone.0001866.g006
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that RXR (where X is any amino acid) correspond to the
consensus site recognized by the protease involved in this cleavage
(unpublished data). Further analyses using protease inhibitors and
small interference RNAs should enable us to identify this protease.
Pulse-chase experiments in CHO cells showed that the cleavage
occurs after N-glycan maturation (unpublished data), suggesting
that it likely involves a Golgi resident protease. We showed that a
RGRR furin cleavage motif made by insertion of an Arg residue
into the EWI-2 sequence allows efficient production of EWI-2wint
and additional cleavage product(s) in Huh-7 cells. As shown here,
EWI-2 can be cleaved at RGR site to produce EWI-2wint, and it
is likely that a furin-like protease may be responsible for this
cleavage. Such a protease may be expressed differently among cell
types, such that liver cells lacking the enzyme are consequently
more sensitive to HCV infection. On the other hand, the
accessibility of EWI-2 to protease(s) may be cell-type specific and
might be modulated by other components of the tetraspanin webs
that vary in different cell types [14,16].
Although several molecules have already been implicated in the
entry process of HCV, it is likely that additional specific factors
regulate its entry into hepatic cells [41]. Silencing of endogenous
EWI-2 in Huh-7 cells did not significantly affect HCVcc infection
(data not shown) indicating that while being a major partner of
CD81, EWI-2 is likely not involved in the HCV entry process.
Here, we showed that EWI-2wint, present in some cell lines and
absent from hepatic cells, is able to inhibit HCV entry. The
production of a mAb directed against EWI-2wint will be essential
to further analyse the expression profile of EWI-2wint in various
tissues and cell lines. Nevertheless, our results suggest that, in
addition to the presence of specificentry factorsin the hepatocytes
such as CD81, SR-BI, CLDN-1 and additional unidentified
molecule(s), the absence of a specific inhibitor can also contribute
to the hepatotropism of HCV. Interestingly, 293T cells, that are
permissive for HCV entry when they express CLDN-1 [11], do
not express EWI-2wint (Table 1). Further experiments with HCV
non permissive cells expressing all known positive entry factors
will be necessary to determine if the silencing of endogenous EWI-
2wint is sufficient to induce HCV permissivity.
In conclusion, our observation constitutes a basis for the rational
design of new antiviral molecules. Moreover, it represents a new
mechanism that contributes to the regulation of the entry of a
pathogen into a host cell.
Materials and Methods
Cells and antibodies
U937-CD81 cells have been described previously [42]. Primary
hepatocytes were isolated from three human foetal livers
(Advanced Bioscience Resources, Inc, Alameda, CA). HepG2-
CD81 [10] have been described previously and were kindly
provided by F-L. Cosset.
The mAbs used in this study included: 5A6 (anti-CD81 [43]),
8A12 (anti-EWI-2 [18]), 1F11 (anti-EWI-F [19]), H53 (anti-HCV
E2 [44]), 3/11 (anti-HCV E2, kindly provided by J. McKeating
[45]), ACAP27 and 486-D39 (anti-HCV core and HCV NS3,
respectively, kindly provided by JF Delagneau [46]). The anti-beta
actin (clone AC-15), the M2 anti-FLAG epitope mAb and the M2
anti-FLAG affinity gel were from Sigma. The HA11 (anti-HA,
Clone 16B12) mAb was from Covance. The anti-claudin-1 (JAY.8)
was from Zymed Laboratories. The anti-SR-BI (Cla-1) was from
BD Transduction Laboratories.
Plasmids
pcDNA3.1/CD81 plasmid has been described previously [18].
EWI-2 was FLAG-tagged (DYKDDDDK) at its C-terminus by
polymerase chain reaction (PCR) amplification from template
pCMVSport6/EWI-2 [18] and subcloned into a pcDNA3.1 vector
(pcDNA3.1/EWI-2FLAG). Three Gly residues were introduced
between EWI-2 and FLAG epitope sequences to increase epitope
accessibility. Plasmid pcDNA3.1/wint-FLAG encoding EWI-2
signal peptide (amino acids 1–25) and EWI-2 amino acids 166–
613 fused to FLAG tag was made by fusion-PCR from template
pcDNA3.1/EWI-2FLAG. pcDNA3.1/HAEWI-2FLAG encodes
EWI-2 signal peptide followed by HA9 epitope (YPYDVPDYA)
tag fused to the entire sequence of EWI-2FLAG. Three Gly
residues were also introduced between HA epitope and EWI-
Figure 7. EWI-2wint inhibits the infection of both HCVcc and
HCVpp. A, Cellular populations (pcDNA3.1, HAEWI-2FLAG and EWI-
2FLAG
fur POP) and individual cellular clones (EWI-2FLAG
fur A1, A6, B14,
C1) were infected with HCVcc expressing Renilla luciferase (R-Luc). In
parallel, these cells were infected with HCVpp 1a, HCVpp 2a or VSVpp
expressing firefly luciferase (F-Luc) (B), as described in Figure 6. At
2 days post-infection, cells were lysed and processed to measure the
luciferase activity. The luciferase activities were normalized for protein
concentration in each cell lysate. The results are presented as relative
percentages to HCVcc (A) and HCVpp (B) infectivity on Huh-7 cells.
HCVpp infections (B) were also normalized to VSVpp infections on Huh-
7 cells. Results are reported as the mean6S.D. of three independent
experiments.
doi:10.1371/journal.pone.0001866.g007
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fur plasmid, an Arg
residue was introduced between EWI-2 amino acids 165 and 166.
Cloning details and oligonucleotide sequences are available upon
request.
Cell transfection
CHO cells were transfected using ExGen500 (Eurogentec).
CHO/CD81+EWI-2FLAG cell line was obtained by selection for
2 weeks with 500 mg/ml hygromycin and 800 mg/ml neomycin.
The resulting cells were maintained in selection media as a
polyclonal population. For stably transfected Huh-7 cells, cells
were electroporated using the Gene Pulser apparatus (Bio-Rad)
and neomycin was added 48 hours post-transfection at 600 mg/
ml. After 2 weeks, isolated clones were split using selection
cylinders and maintained in neomycin medium.
CD81-E1E2 interaction assay
COS-7 cells were infected with a recombinant adenovirus (Ad)
expressing the HCV proteins E1, E2, p7 and NS2 (Ad/
E1E2p7NS2, amino acids 171–1026) [27] at a multiplicity of
25PFU per cell. At 48 h post-infection, cells were washed twice
with ice-cold Dulbecco’s phosphate-buffered saline (D-PBS), and
lysed in one of the following lysis buffers : 1% Brij97 in D-PBS
with calcium and magnesium (Bj/CaMg) or with 2 mM EDTA
(Bj/EDTA), 1% Triton X-100 in D-PBS with calcium and
magnesium (TX/CaMg), or with 2 mM EDTA (TX/EDTA).
Clarified lysates were then incubated with mAb H53 pre-
adsorbed onto rabbit anti-mouse protein A-sepharose overnight
at 4uC (beads-E1E2). In parallel, rabbit anti-mouse-protein A
beads were incubated with mAb 5A6 (beads-CD81) or an
irrelevant control mouse mAb (beads-Cont). Cell lines were lysed
in Bj/CaMg, Bj/EDTA, TX/CaMg or TX/EDTA lysis buffer at
10610
6 cells/ml, clarified and incubated with beads-E1E2,
beads-CD81 and beads-Cont for 6 h at 4uC. After rinsing five
times with the lysis buffer, complexes were eluted in non-
reducing sample buffer, resolved by SDS-PAGE, and immuno-
blotted with mAb 5A6.
Detection of cell surface biotinylated proteins
Cells were biotinylated as previously described [19] with
0.2 mg/ml EZ-link-Sulpho-NHS-LC-biotin (Pierce), and lysed
into Bj/EDTA or TX/EDTA containing protease inhibitors
(Complete, Roche). Lysates were precleared for 2 h at 4uC with
protein A-sepharose (Amersham Biosciences) then incubated with
mAbs pre-adsorbed onto rabbit anti-mouse-protein A beads for
2 h at 4uC. After rinsing, complexes were eluted, resolved by SDS-
PAGE, and immunoblotted with peroxidase-conjugated streptavi-
din (Vector).
EWI-2 silencing
To silence the expression of endogenous EWI-2 protein, Daudi
cells were electroporated with negative siRNA directed against the
FLAG epitope (59 AUUACAAGGACGACGAUGA 39, Dharma-
con) and EWI-2 siRNA directed against the sequence 59
GUUCUCCUAUGCUGUCUU 39 (Dharmacon) corresponding
to nucleotide sequence 253–270 of the ORF of EWI-2 [23]. Daudi
cells were electroporated at 4uC using the Gene Pulser apparatus
(400V, 950uF). Seventy two hours post-transfection, cells were
biotinylated, lysed in Bj/EDTA and immunoprecipitated with
5A6 and 8A12 mAbs. Immunoprecipitated proteins were revealed
by Western blotting with peroxidase-conjugated streptavidin or
5A6 mAb.
Flow cytometry analysis
After trypsinization, transfected cells were fixed with Formalin
Solution (formaldehyde 4%, Sigma) and permeabilized with PBS
0.2% BSA 0.05% Saponin. After rinsing with PBS 2% BSA 2 mM
EDTA, cells were incubated 1 h at 4uC with 486-D39 anti-NS3
mAb. After rinsing with washing solution, cells were incubated
with PE labeled goat anti-mouse (BD Pharmingen) for 45 min at
4uC, then washed and fixed with Formalin Solution. For CD81
staining, cells were detached with PBS 2 mM EDTA and
incubated 1 h at 4uC with 5A6 anti-CD81 mAb. After rinsing
with washing solution, cell lines were incubated with PE labeled
goat anti-mouse for 45 min at 4uC, then washed and fixed with
Formalin Solution (PFA 10%, Sigma). Cells stained only with the
secondary antibodies were used as negative control. Labeled cells
were analyzed using a FACS Beckman EPICS-XL MCL.
Protein purification, mass spectrometry and N-terminal
sequencing
For purification of EWI-2FLAG and wint-FLAG, ,2610
8
CHO/CD81+EWI-2FLAG cells were lysed in 20 mM Tris-HCl,
150 mM NaCl, pH 7.6 (TBS), 1 mM EDTA and 1% Triton X-
100 in the presence of protease inhibitors. Clarified cell lysates
were precleared for 2 h at 4uC with protein A-sepharose and then
incubated with an anti-FLAG M2 affinity gel for 2 h at 4uC. After
five washes with TBS containing 0.2% Triton X-100 (TBS-T),
FLAG-tagged proteins were eluted with 100 mg/ml FLAG peptide
(Sigma) in TBS-T. Purified proteins were then precipitated with 5
volumes of acetone, incubated overnight at 220uC, and
centrifugated. After rinsing with 80% acetone, proteins were
resuspended in sample buffer, and resolved by SDS-PAGE.
Colloı ¨dal blue stained bands corresponding to EWI-2FLAG and
wint-FLAG were then excised from the gel, reduced, alkylated
with iodoacetamide (10 mg/ml in NH4HCO3, 20 mM) and
digested overnight with 50 ng trypsin (Promega) in 20 mM
NH4HCO3, or 100 ng V8 endoproteinase Glu C (Roche) in
0.1 M phosphate buffer pH7.7. The resulting peptide mixture was
eluted from the gel, desalted, and spotted on a Maldi plate with
freshly dissolved a-cyano-4-hydroxycinnaminic acid (5 mg/ml in
50% CH3CN, 20 mM citric acid). The dried spot was then
washed with 20 mM di-ammonium citrate pH 4.5. Mass
spectrometry was performed with a MALDI-TOF Voyager-DE-
STR (Applied Biosystems). Spots were analysed by setting the
following parameters: positive and reflector modes, acceleration
voltage of 20KV, grid voltage of 61%, 90 ns of delayed extraction,
low mass gate 500 amu. The laser energy required to desorb/
ionise the samples was kept at low value, compatible with a good
signal/noise ratio. Spectra were calibrated externally by using the
[M+H+] monoisotopics ions from trypsinized lyzozyme. The
theoretical list of digested peptides was obtained using MS-Digest
http://128.40.158.151/ucsfhtml3.4/msdigest.htm. For N-termi-
nal sequencing, purified proteins were transferred to PVDF and
stained with amido black. Blotted EWI-2FLAG and wint-FLAG
were sequenced in a Procise 492 sequanator (Applied Biosystems)
using pulsed-liquid method.
JFH-1 infection
The plasmid pJFH1, containing the full-length cDNA of JFH1
isolate (genotype 2a) and kindly provided by T. Wakita (National
Institute of Infectious Diseases, Japan), was used to generate
HCVcc as described [6,47]. Infectious titers of viral stocks were
estimated between 10
5 and 10
6 focus-forming units per ml, based
on immunofluorescent detection of infected foci following infection
of Huh-7 cells with serial dilutions of viral stocks. Cell lines were
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incubated for additional 40 h at 37uC. Infections were scored by
indirect immunofluorescence with anti-C mAb ACAP27 followed
by Alexa
488-conjugated goat anti-mouse (Jackson Immunore-
search). Fifteen micrograms of total protein were also analyzed
by immunoblotting with 3/11 mAb followed by peroxidase-
conjugated goat anti-rat immunoglobulins (Jackson Immunore-
search). The blots were then stripped and reprobed with an anti-
beta actin followed by peroxidase-conjugated goat anti-mouse
immunoglobulins (Sigma). Quantification of protein expression
was performed using NIH Image 1.62 from the band mean
densities.
To generate HCVcc expressing Renilla luciferase, we used the
FL-J6/JFH-59C19Rluc2AUbi genome [48] kindly provided by
C.M. Rice. We replaced the region encoding the J6/JFH-1 HCV
polyprotein with the CS-N6 JFH-1 sequence [47]. HCVcc were
produced as described [6,47,48]. HCVcc were added to Huh-7
cells (m.o.i.=1) seeded the day before in 24-well plates and
incubated for 2 h at 37uC. The supernatants were then removed
and the cells were incubated in DMEM 10% FBS at 37uC. At 40–
48 h post-infection, Renilla luciferase assays were performed as
indicated by the manufacturer (Promega).
HCVcc replication analyses
In vitro transcribed full-length JFH1 RNA was transfected by
electroporation as described [49]. At 40 h post-transfection, cells
were analyzed by indirect immunofluorescence and flow cytometry.
Indirect immunofluorescence microscopy
Infected or transfected cells grown on coverslips were fixed with
3% paraformaldehyde and permeabilized with 0.05% Triton X-
100 in PBS. Cells were then stained with anti-C mAb ACAP27
followed by Alexa
488-conjugated goat anti-mouse (Jackson Im-
munoresearch). Coverslips were mounted on glass slides using
Mowiol, and observed with a Zeiss Axioplan 2 Axiophot 2
equipped with a 206/1.3 numerical aperture lens. Fluorescent
signals were collected with a Princeton cooled charged device
using specific fluorescence excitation and emission filters. Images
were processed with Adobe Photoshop software.
Production of HCVpp and infection assays
HCVpp were produced as described previously [3,50] with
plasmids kindly provided by B. Bartosch and F.L. Cosset
(INSERM U412, Lyon, France). For the production of VSVpp,
a plasmid encoding the vesicular stomatitis virus glycoprotein G
[51] was used. Supernatants containing the pseudotyped particles
were harvested 48 h after transfection, filtered through 0.45-mm
pore-sized membranes and conserved at 4uC. HCVpp were added
to Huh-7 cells seeded the day before in 24-well plates and
incubated for 2–3 h at 37uC. The supernatants were then
removed and the cells were incubated in DMEM 10% FBS at
37uC. At 48 h post-infection, luciferase assays were performed as
indicated by the manufacturer (Promega).
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